Nakamura Masaru, Nagamine Takahiko
Dr. Nakamura is with the Department of Psychiatric Internal Medicine, Kosekai-Kusatsu Hospital in Hiroshima, Japan.
Dr. Nagamine is with the Department of Psychiatric Internal Medicine, Sunlight Brain Research Center in Yamaguchi, Japan.
Innov Clin Neurosci. 2019 Sep 1;16(9-10):30-32.
Atypical antipsychotics, used to treat patients with schizophrenia, focus on dopamine-2 (D) plus serotonin-2A (5-HT) receptor antagonism and currently carry different degrees of certain adverse effects. Brexpiprazole is a new serotonin-dopamine receptor modulator that acts as a partial agonist at the 5-HT and D receptors. In patients who were either introduced to brexpiprazole because of nonadherence to traditional medications or were switched from apripiprazole, olanzapine, or paliperidone, the impact of brexpiprazole on different parameters was evaluated. Ultimately, it was found that brexpiprazol treatment displayed a low propensity to influence metabolic parameters (lipids and glucose) and minimal impact on prolactin levels. Further prospective and longer follow-up studies involving larger groups of subjects are required.
非典型抗精神病药物用于治疗精神分裂症患者，主要作用于多巴胺-2（D2）和5-羟色胺-2A（5-HT2A）受体的拮抗作用，目前存在不同程度的特定不良反应。布雷哌唑是一种新型的5-羟色胺-多巴胺受体调节剂，对5-HT2A和D2受体起部分激动剂的作用。对于那些因不依从传统药物治疗而改用布雷哌唑，或从阿立哌唑、奥氮平或帕利哌酮换药而来的患者，评估了布雷哌唑对不同参数的影响。最终发现，布雷哌唑治疗对代谢参数（脂质和血糖）影响的倾向较低，对催乳素水平的影响最小。还需要进一步开展涉及更大样本量受试者的前瞻性和长期随访研究。
